Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Wyeth Pharmaceuticals France
Woman and Man Max 99 years
Wyeth Pharmaceuticals France
Update Il y a 4 ans
A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients with Active, Severe and Advanced Axial Ankylosing Spondylitis
To compare the efficacy of etanercept (50 mg, once weekly) with that of placebo in patients with active, severe and advanced Ankylosis Spondylitis (as defined by the modified New York criteria) at wee...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals France
Update Il y a 4 ans
A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Auto-Injector and the Etanercept Prefilled Syringe) in Patients with Rheumatoid Arthritis
To compare patient satisfaction with two different delivery devices for etanercept after 12 weeks of use, using a 10 point scale form totally dissatisfied to totally satisfied.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals France, Wyeth Research Division
Update Il y a 4 ans
An open-label, multicentre, supplementary and extension study of Etanercept in subjects with Ankylosing Spondylitis (AS)
To evaluate the health care resource utilization and work status in patients with ankylosing spondylitis by comparing study evaluations with the baseline evaluations in the ASCEND 0881A3-402-WW Study.
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Wyeth Pharmaceuticals France
Update Il y a 4 ans
Reformulated BeneFIX efficacy and safety after conversion from a pdFIX
To collect data around the period of the conversion from pdFIX to BeneFIX in patients for whom a conversion to BeneFIX has already been decided by the investigator. The main following parameters will ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals France
Update Il y a 4 ans
A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Autoinjector and the Etanercept Prefilled Syringe) in Patients with Psoriasis
To compare patient satisfaction with two different delivery devices for etanercept after 12 weeks of use, using a 10 point scale form totally dissatisfied to totally satisfied.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals France
Update Il y a 4 ans
A Randomised, Open-Label Preliminary Study To Assess The Effects Of Etanercept 50 mg Once Weekly For 24 Weeks And Etanercept 50 mg Twice Weekly For 12 weeks Reducing To Etanercept 50 mg Once Weekly For 12 weeks On Nail And Skin Symptoms In Patients With Nail Psoriasis And Plaque Psoriasis
To estimate the Nail Psoriasis Severity Index (NAPSI) in the target fingernail for both treatment regimens over 24 weeks.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals France
Update Il y a 4 ans
An Open-Label, Randomized Study To Evaluate The Radiographic Efficacy And Safety Of Enbrel™ (Etanercept) Added To Methotrexate In Comparison With Usual Treatment In Subjects With Moderate Rheumatoid Arthritis Disease Activity
To evaluate the impact of ETN + MTX in comparison with usual treatment on radiographic disease progression at 52 weeks in subjects with moderate RA who failed treatment with MTX.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals France
Update Il y a 4 ans
'A multicenter double-blind, placebo-controlled randomized pilot study evaluating efficacy and safety of ETN in patients with moderate to severe plaque psoriasis after cessation of ciclosporin therapy'
To demonstrate the sustained efficacy and safety of etancercept as a replacement therapy for ciclosporin in patients with moderate to severe plaque psoriasis who have achieved an adequate response wit...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals France, Wyeth Research Division
Update Il y a 4 ans
A phase II a , Multicenter, Randomized , Third -party Unblinded , Long- term Extension study to Determine Safety, Tolerability and Immunogenicity of ACC-001 with and without QS21 Adjuvant in Subjects with Mild to Moderate Alzheimzer's Disease Estudio de fase IIa, multicéntrico, aleatorizado y con tercera parte conocedora del tratamiento, de extensión a largo plazo, para determinar la seguridad, la tolerabilidad y la inmunogenicidad de ACC-001, con y sin adyuvante QS-21, en sujetos con enfermedad de Alzheimer de grado leve a moderado
The primary objective of the study is to evaluate the long-term safety and tolerability of doses of 3, 10, and 30 µg of ACC-001 (CRM-conjugated A-beta [1-7] antigen alone and in combination with QS-21...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals France
Update Il y a 4 ans
A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study To Explore And Compare Perceptions And Satisfaction For Two Different Delivery Mechanisms For Etanercept (Etanercept Autoinjector And The Etanercept Prefilled Syringe) In Patients With Rheumatoid Arthritis
To compare patient satisfaction with two different delivery devices for etanercept after 12 weeks of use, using a 10 point scale form totally dissatisfied to totally satisfied.
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
Next